Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Keytruda Reaches Blockbuster Status, But Still Lags In Lung Cancer

03 Feb 2017

• By Joseph Haas

T-cell

Related Content

Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain

21 Jan 2017

Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds

21 Jan 2017

Under Fire, Bristol Plans To Pick Up The IO Pieces

27 Jan 2017

Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics

11 Jan 2017

Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch

25 Oct 2016

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

10 Oct 2016

PD-1 Deep Dive: Lung Cancer Market Braced For Change

06 Nov 2016

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Roche Holding AG

AstraZeneca PLC

Eli Lilly and Company

Additional Topics

Sales & Earnings ImmunoOncology Commercial Cancer BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.